BACKGROUND AND PURPOSE: In order to use a single implant with one treatment plan in fractionated high-dose-rate brachytherapy (HDR-B), applicator position shifts must be corrected prior to each fraction. The authors investigated the use of gold markers for X-ray-based setup and position control between the single fractions. PATIENTS AND METHODS: Caudad-cephalad movement of the applicators prior to each HDR-B fraction was determined on radiographs using two to three gold markers, which had been inserted into the prostate as intraprostatic reference, and one to two radiopaque-labeled reference applicators. 35 prostate cancer patients, treated by HDR-B as a monotherapy between 10/2003 and 06/2006 with four fractions of 9.5 Gy each, were analyzed. Toxicity was scored according to the CTCAE Score, version 3.0. Median follow-up was 3 years. RESULTS: The mean change of applicators positions compared to baseline varied substantially between HDR-B fractions, being 1.4 mm before fraction 1 (range, -4 to 2 mm), -13.1 mm before fraction 2 (range, -36 to 0 mm), -4.1 mm before fraction 3 (range, -21 to 9 mm), and -2.6 mm at fraction 4 (range, -16 to 9 mm). The original position of the applicators could be readjusted easily prior to each fraction in every patient. In 18 patients (51%), the applicators were at least once readjusted > 10 mm, however, acute or late grade > or = 2 genitourinary toxicity was not increased (p = 1.0) in these patients. CONCLUSION: Caudad position shifts up to 36 mm were observed. Gold markers represent a valuable tool to ensure setup accuracy and precise dose delivery in fractionated HDR-B monotherapy of prostate cancer.
BACKGROUND AND PURPOSE: In order to use a single implant with one treatment plan in fractionated high-dose-rate brachytherapy (HDR-B), applicator position shifts must be corrected prior to each fraction. The authors investigated the use of gold markers for X-ray-based setup and position control between the single fractions. PATIENTS AND METHODS: Caudad-cephalad movement of the applicators prior to each HDR-B fraction was determined on radiographs using two to three gold markers, which had been inserted into the prostate as intraprostatic reference, and one to two radiopaque-labeled reference applicators. 35 prostate cancerpatients, treated by HDR-B as a monotherapy between 10/2003 and 06/2006 with four fractions of 9.5 Gy each, were analyzed. Toxicity was scored according to the CTCAE Score, version 3.0. Median follow-up was 3 years. RESULTS: The mean change of applicators positions compared to baseline varied substantially between HDR-B fractions, being 1.4 mm before fraction 1 (range, -4 to 2 mm), -13.1 mm before fraction 2 (range, -36 to 0 mm), -4.1 mm before fraction 3 (range, -21 to 9 mm), and -2.6 mm at fraction 4 (range, -16 to 9 mm). The original position of the applicators could be readjusted easily prior to each fraction in every patient. In 18 patients (51%), the applicators were at least once readjusted > 10 mm, however, acute or late grade > or = 2 genitourinary toxicity was not increased (p = 1.0) in these patients. CONCLUSION: Caudad position shifts up to 36 mm were observed. Gold markers represent a valuable tool to ensure setup accuracy and precise dose delivery in fractionated HDR-B monotherapy of prostate cancer.
Authors: Y Yoshioka; T Nose; K Yoshida; T Inoue; H Yamazaki; E Tanaka; H Shiomi; A Imai; S Nakamura; S Shimamoto; T Inoue Journal: Int J Radiat Oncol Biol Phys Date: 2000-10-01 Impact factor: 7.038
Authors: Michael Pinkawa; Bernd Gagel; Marc Dieter Piroth; Holger Borchers; Gerhard Jakse; Michael J Eble Journal: Strahlenther Onkol Date: 2006-09 Impact factor: 3.621
Authors: Alvaro A Martinez; Gary Gustafson; José Gonzalez; Elwood Armour; Chris Mitchell; Gregory Edmundson; William Spencer; Jannifer Stromberg; Raywin Huang; Frank Vicini Journal: Int J Radiat Oncol Biol Phys Date: 2002-06-01 Impact factor: 7.038
Authors: Razvan M Galalae; Alvaro Martinez; Tim Mate; Christina Mitchell; Gregory Edmundson; Nils Nuernberg; Stephen Eulau; Gary Gustafson; Michael Gribble; Gyoergy Kovács Journal: Int J Radiat Oncol Biol Phys Date: 2004-03-15 Impact factor: 7.038
Authors: Inga S Grills; Alvaro A Martinez; Mitchell Hollander; Raywin Huang; Kenneth Goldman; Peter Y Chen; Gary S Gustafson Journal: J Urol Date: 2004-03 Impact factor: 7.450
Authors: J F Langenhuijsen; R Donker; G M McColl; L A L M Kiemeney; J A Witjes; E N J T van Lin Journal: Strahlenther Onkol Date: 2013-04-21 Impact factor: 3.621
Authors: Pirus Ghadjar; Sebastian L Oesch; Cyrill A Rentsch; Bernhard Isaak; Nikola Cihoric; Peter Manser; George N Thalmann; Daniel M Aebersold Journal: Radiat Oncol Date: 2014-05-28 Impact factor: 3.481